RMD

ResMed Inc. 10-K Summary: Fiscal Year Ended June 30, 2001

Business Context and Reporting Period

This report covers the fiscal year ended June 30, 2001, for ResMed Inc., a leading developer and manufacturer of medical equipment for treating sleep disordered breathing (SDB), primarily obstructive sleep apnea (OSA). The company operates globally with manufacturing in Australia and sales in over 60 countries. A significant event during the period was the acquisition of MAP Medizin-Technologie GmbH in February 2001, a German medical device company, which strengthened ResMed's position in the European market.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 34% to $155.2 million, driven by higher unit sales in North America ($79.9M vs $62.7M) and Europe ($60.5M vs $40.5M). Growth was partially offset by unfavorable European foreign exchange rates.
• Profitability Decline: Despite revenue growth, net income dropped 48% to $11.6 million. This was primarily due to a one-time non-recurring charge of $17.7 million for purchased in-process research and development (IPR&D) related to the MAP acquisition, and a $0.55 million restructuring charge.
• Debt Issuance: The company issued $150 million in 4% convertible subordinated notes due in 2006 (plus an additional $30 million via over-allotment in July 2001) to fund the MAP acquisition and expansion. This resulted in a significant increase in long-term debt from zero to $150 million.
• Expense Increases: Selling, general, and administrative (SG&A) expenses rose 33% to $49.4 million due to increased personnel and sales activities. R&D expenses increased 31% to $11.1 million.

Outlook, Risks, and Management Commentary

• Acquisition Integration: Management expects European sales to increase as a percentage of total revenue following the MAP acquisition. The company is currently integrating MAP's operations, which carries risks regarding personnel retention and operational synergy.
• Product Pipeline: ResMed continues to invest in innovation, with mask interface systems expected to be commercially available in 2002 and autotitrating devices between 2003 and 2005. A device for Cheyne-Stokes breathing in heart failure patients is in development but not yet approved in the U.S.
• Key Risks:
  • Reimbursement: Sales depend heavily on third-party reimbursement (Medicare, Medicaid, private insurers). Changes in reimbursement policies or price controls in markets like Europe and Australia could negatively impact sales.
  • Competition: The market is highly competitive with major players like Respironics, DeVilbiss, and Nellcor Puritan Bennett. Consolidation in the healthcare industry may increase competitive pressure.
  • Foreign Currency: Significant exposure to the Australian dollar and Euro. Fluctuations can materially affect reported sales and earnings.
  • Intellectual Property: Ongoing litigation with Respironics regarding patent infringement remains unresolved, with summary judgment motions granted against ResMed in the U.S. district court.
• Liquidity: The company maintains strong liquidity with $102.8 million in cash and marketable securities, sufficient to meet short-term requirements.

Investor Verification Checklist

• Verify the status and potential financial impact of the ongoing patent litigation with Respironics.
• Monitor the integration progress of the MAP acquisition and the realization of projected European revenue growth.
• Track changes in third-party reimbursement policies in the U.S. and key European markets (Germany, France, Spain).
• Assess the impact of foreign exchange rate fluctuations, particularly the Australian dollar, on future margins.
• Review the timeline and regulatory approval status for new product launches, specifically the Cheyne-Stokes device and new mask systems.